Antibody-Enzyme Fusion Proteins and Bispecific Antibodies
The immunoglobulin molecule is the veritable prototype of a multidomain structure. Each of its units possesses a characteristic function, and in many instances antibody domains can be separated from one another and still retain their functions. The 150 kDa intact molecule can be cleaved to produce the 50 kDa antigen-binding fragment (Fab). A still smaller domain that actually participates in antigen binding, the 25 kDa variable region fragment (Fv), can be produced by recombinant DNA methods. For Fv, Fab, or whole antibody, the affinity for a given epitope is the same. The 50 kDa complement-binding fragment (Fc), another independent immunoglobulin unit, retains the ability to bind the first component of complement and the property of transport across the placental barrier.
KeywordsFusion Protein Plasminogen Activator Heavy Chain Bispecific Antibody Prodrug Activation
Unable to display preview. Download preview PDF.
- Declerck PJ, Lijnen HR, Verstreken M, Moreau H, Collen D (1990) A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma. Blood 75:1794–1800PubMedGoogle Scholar
- Dewerchin M, Lijnen HR, Stassen JM, De Cock F, Quertermous T, Ginsberg MH, Plow FF, Collen D (1991) Effect of chemical conjugation of recombinant singlechain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo. Blood 78:1005–1018PubMedGoogle Scholar
- Gimple LW, Gold HK, Leinbach RC, Coller BS, Werner W, Yasuda T, Johns JA, Ziskind AA, Finkelstein D, Collen D (1989) Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 80:581–588PubMedCrossRefGoogle Scholar
- Holvoet P, Laroche Y, Lijnen HR, Van Cauwenberge R, Demarsin E, Brouwers E, Matthyssens G, Collen D (1991) Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase. J Biol Chem 266:19717–19724PubMedGoogle Scholar
- Huston JS, Levinson D, Mudgett-Hunter M, Tai M-S, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, Oppermann H (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85:5879–5883PubMedCrossRefGoogle Scholar
- Kurokawa T, Iwasa S, Kakinuma A (1989) Enhanced fibrinolysis by a bispecific monoclonal antibody reactive to fibrin and tissue plasminogen activator. Biotechnology 7:1163–1167Google Scholar
- Near RI, Ng SC, Mudgett-Hunter M, Hudson NW, Margolies MN, Seidman JG, Haber E, Jacobson MA (1990) Heavy and light chain contributions to antigen binding in an antidigoxin chain recombinant antibody produced by transfection of cloned anti-digoxin antibody genes. Mol Immunol 27:901–909PubMedCrossRefGoogle Scholar
- Runge MS, Quertermous T, Zavodny PJ, Love TW, Bode C, Freitag M, Shaw S-Y, Huang PL, Chou C-C, Mullins D, Schnee JM, Savard CE, Rothenberg ME, Newell JB, Matsueda GR, Haber E (1991) A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo. Proc Natl Acad Sci USA 88:10337–10341PubMedCrossRefGoogle Scholar
- Springer CJ, Bagshawe KD, Sharma SK, Searle F, Boden JA, Antoniw P, Burke PJ, Rogers GT, Sherwood RF, Melton RG (1991) Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur J Cancer 27:1361–1366PubMedCrossRefGoogle Scholar